Last Updated: 04/06/07

James H. Doroshow, M.D., FACP
Director of the Division of Cancer Treatment and Diagnosis

NCI Experimental Therapeutics Program (NExT)

As part of the change process, DCTD and the Center for Cancer Research (CCR) are working in close collaboration to reinvigorate cancer drug development at NCI. Through the new, NCI Experimental Therapeutics Program (NExT), extramural and intramural teams have prioritized a pipeline of NCI-driven targeted therapeutics for development. This joint program combines the strengths of DCTD’s extensive expertise in anticancer drug development with CCR’s dynamic in-house research and its location within new state-of-the-art facilities at the NIH Clinical Research Center. This collaboration will also utilize a recent guidance from the U.S. Food and Drug Administration concerning exploratory studies of investigational new drugs.